MaaT Pharma Announces Update on Clinical Trial Authorization Application Filed with the FDA for MaaT013 in Patients With Acute Graft Versus Host Disease

MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotechnology company pioneering the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving the survival of cancer patients, announces today that it has received a communication from the US Food and Drug Administration (“the FDA” or “the Agency”) in connection with the clinical trial authorization application, or Investigational New Drug application (IND), submitted in June 2021 and relating to the initiation of United States of an open-label, single-arm Phase 3 clinical trial evaluating MaaT013, the Company’s drug candidate, in patients with acute graft-versus-host disease (aGvH) and resistant to steroids.

To receive all of MaaT Pharma’s financial information in real time and for any questions, you can contact us via the following address: [email protected]

Source link -86